ADULT AIDS CLINICAL RESEARCH

成人艾滋病临床研究

• 批准号: 3727017
• 负责人: CHARLES VAN DER HORST
• 金额: --
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3727017
• 关键词: AIDS; AIDS therapy; DNA topoisomerases; Epstein Barr virus; HIV infections; Herpesviridae; Pneumocystis carinii; Pneumocystis pneumonia; antiAIDS agent; antiviral agents; chemoprevention; clinical trials; cooperative study; cytomegalovirus; enzyme inhibitors; female; flow cytometry; human subject; human therapy evaluation; immunology; infection related neoplasm /cancer; intravenous drug abuse; medical complication; microorganism disease chemotherapy; neurology; opportunistic infections; pentamidine; pharmacokinetics

We propose to continue our multidisciplinary research program which will integrate substantial institutional expertise in infectious diseases, neurology, immunology, retrovirology and herpes viruses, parasitology, agents active against these agents, and numerous clinical resources in both South Carolina and North Carolina focusing on the evaluation of novel therapies for HIV-infected persons. A group of clinical investigators at UNC as well as 4 satellite units in Charlotte, Greensboro, Raleigh and Charleston, South Carolina will collectively study new compounds active against HIV and associated diseases in 150 new patients and 277 previously enrolled patients in a timely and cost-effective manner. We shall continue our high rate of accrual among minorities, women and IVDUs. Trials will be of all phases (I, II, III) and types (primary infection, opportunistic infection, neurology, malignancy). Patients will be followed for in vivo evidence of study drug effects on HIV, EBV, CMV, HSV and other opportunistic infections using our core virology laboratory. Pharmacokinetics will be monitored in our General Clinical Research Center. Concepts for new protocols will originate with the investigators, through participation in ACTG committees and the newly established scientific advisory board. Outreach to the community and local physicians will be accomplished through our community advisory boards at each site, our statewide newsletter, and continuing education lectures around the state. Links will continue with 5 other major NIH-funded clinical research grants and 4 different NIH training grants.

我们建议继续我们的多学科研究计划，这将 整合传染病方面的大量机构专门知识， 神经学，免疫学，逆转录病毒学和疱疹病毒，寄生虫学， 积极对抗这些药物的药物，以及这两种药物中的大量临床资源 南卡罗来纳州和北卡罗来纳州重点评价小说 艾滋病毒感染者的治疗。一组临床研究人员在 北卡罗来纳大学以及夏洛特、格林斯伯勒、罗利和 南卡罗来纳州查尔斯顿将集体研究新的活性化合物 在150名新患者和277名以前的患者中预防艾滋病毒和相关疾病 以及时和具有成本效益的方式招募患者。我们将继续 我们在少数族裔、妇女和静脉注射吸毒者中的高应收率。审判将是 所有阶段(I、II、III)和类型(原发感染、机会性 感染、神经病学、恶性肿瘤)。患者将被跟踪进行体内试验 研究药物对HIV、EBV、CMV、HSV和其他病毒影响的证据 利用我们的核心病毒学实验室进行机会性感染。 药代动力学将在我们的综合临床研究中心进行监测。 新协议的概念将源自调查人员，通过 参加ACTG委员会和新成立的科学委员会 顾问委员会。与社区和当地医生的接触将是 通过我们在每个站点的社区咨询委员会完成，我们的 全州范围的时事通讯，以及全州各地的继续教育讲座。 将继续与NIH资助的其他5项主要临床研究拨款建立联系 和4种不同的NIH培训补助金。